These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12948166)

  • 1. Serious allergic reaction to administration of epirubicin.
    Oltmans R; van der Vegt SG
    Neth J Med; 2003 Jun; 61(6):226-7. PubMed ID: 12948166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug eruption due to intravesical instillations of both epirubicin and mitomycin C.
    Okumura A; Oishi N; Kaji K; Imamura T; Fuse H
    J Dermatol; 2009 Jul; 36(7):419-22. PubMed ID: 19583691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
    Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
    Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergic contact dermatitis due to epirubicin.
    Ventura MT; Dagnello M; Di Corato R; Tursi A
    Contact Dermatitis; 1999 Jun; 40(6):339. PubMed ID: 10385350
    [No Abstract]   [Full Text] [Related]  

  • 5. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplastic drugs.
    Bursztejn AC; Tréchot P; Cuny JF; Schmutz JL; Barbaud A
    Contact Dermatitis; 2008 Jun; 58(6):365-8. PubMed ID: 18503688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
    Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
    J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An exceptional case of hypersensitivity to actinomycin D. Case report and review of the literature].
    Cappelli C; Fornari C; De Ioris MA; Russo D; Clerico A
    Clin Ter; 2001; 152(5):319-21. PubMed ID: 11794853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
    Mercuro G; Cadeddu C; Piras A; Dessì M; Madeddu C; Deidda M; Serpe R; Massa E; Mantovani G
    Oncologist; 2007 Sep; 12(9):1124-33. PubMed ID: 17914082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of venous pain and phlebitis caused by epirubicin hydrochloride.
    Sugimoto M; Matsui M; Harada M; Yamauchi Y; Moriyama N; Andou K; Yamamoto M; Yamaoka H; Ono C; Ishikawa M; Kamo N; Ikeda T; Yamaoka K
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):969-74. PubMed ID: 19542717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vasculitic condition following instillation of epirubicin hydrochloride in an outpatient chemotherapy].
    Nakazawa Y; Matsubara Y; Suzuki M; Asako E; Honda A
    Gan To Kagaku Ryoho; 2005 Dec; 32 Suppl 1():24-6. PubMed ID: 16422479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
    Mantovani G; Madeddu C; Cadeddu C; Dessì M; Piras A; Massa E; Serpe R; Antoni G; Mercuro G
    Oncologist; 2008 Dec; 13(12):1296-305. PubMed ID: 19060235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
    Galetta F; Franzoni F; Cervetti G; Cecconi N; Carpi A; Petrini M; Santoro G
    Biomed Pharmacother; 2005 Dec; 59(10):541-4. PubMed ID: 16325366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline cardiotoxicity: one size does not fit all!
    Hershman DL; Neugut AI
    J Natl Cancer Inst; 2008 Aug; 100(15):1046-7. PubMed ID: 18664649
    [No Abstract]   [Full Text] [Related]  

  • 15. Fatal pneumonitis in children with metastatic rhabdomyosarcoma following whole lung radiotherapy and sequential epirubicin.
    Prestwich RJ; Picton SV; Glaser A; Taylor RE
    Pediatr Blood Cancer; 2007 May; 48(5):586-90. PubMed ID: 16302221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleomycin-induced flagellate dermatitis.
    Vuerstaek JD; Frank J; Poblete-Gutiérrez P
    Int J Dermatol; 2007 Nov; 46 Suppl 3():3-5. PubMed ID: 17973877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
    de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
    O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
    Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
    J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.